Insulin-like Growth Factor-I Inhibits Transcriptional Responses of Transforming Growth Factor-β by Phosphatidylinositol 3-Kinase/Akt-dependent Suppression of the Activation of Smad3 but Not Smad2
Open accessThe DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Insulin-like growth factor-I (IGF-I) and transforming growth factor-β (TGF-β) have been shown to be oncogenic and tumor suppressive, respectively, on prostate epithelial cells. Here we show that IGF-I inhibits the ability of TGF-β to regulate expression of several genes in the non-tumorigenic rat prostatic epithelial line, NRP-152. In these cells, IGF-I also inhibits TGF-β-induced transcriptional responses, as shown by several promoter reporter constructs, suggesting that IGF-I intercepts an early step in TGF-β signaling. We show that IGF-I does not down-regulate TGF-β receptor levels, as determined by both receptor cross-linking and Western blot analyses. However, Western blot analysis reveals that IGF-I selectively inhibits the TGF-β-triggered activation Smad3 but not Smad2, while not altering expression of total Smads 2, 3, or 4. The phosphatidylinositol 3-kinase (PI3K) inhibitor, LY29004 reverses the ability of IGF-I to inhibit TGF-β-induced transcriptional responses and the activation of Smad3, suggesting that the suppression of TGF-β signaling by IGF-I is mediated through activation of PI3K. Moreover, we show that enforced expression of dominant-negative PI3K (DN-p85α) or phosphatidylinositol 3-phosphate-phosphatase, PTEN, also reverse the suppressive effect of IGF-I on TGF-β-induced 3TP-luciferase reporter activity, whereas constitutively active PI3K (p110αCAAX) completely blocks TGF-β-induced 3TP-luciferase reporter activity. Further transfection experiments including expression of constitutively active and dominant-negative Akt and rapamycin treatment suggest that suppression of TGF-β signaling/Smad3 activation by IGF-I occurs downstream of Akt and through mammalian target of rapamycin activation. In summary, our data suggest that IGF-I inhibits TGF-β transcriptional responses through selective suppression of Smad3 activation via a PI3K/Akt-dependent pathway. Insulin-like growth factor-I (IGF-I) and transforming growth factor-β (TGF-β) have been shown to be oncogenic and tumor suppressive, respectively, on prostate epithelial cells. Here we show that IGF-I inhibits the ability of TGF-β to regulate expression of several genes in the non-tumorigenic rat prostatic epithelial line, NRP-152. In these cells, IGF-I also inhibits TGF-β-induced transcriptional responses, as shown by several promoter reporter constructs, suggesting that IGF-I intercepts an early step in TGF-β signaling. We show that IGF-I does not down-regulate TGF-β receptor levels, as determined by both receptor cross-linking and Western blot analyses. However, Western blot analysis reveals that IGF-I selectively inhibits the TGF-β-triggered activation Smad3 but not Smad2, while not altering expression of total Smads 2, 3, or 4. The phosphatidylinositol 3-kinase (PI3K) inhibitor, LY29004 reverses the ability of IGF-I to inhibit TGF-β-induced transcriptional responses and the activation of Smad3, suggesting that the suppression of TGF-β signaling by IGF-I is mediated through activation of PI3K. Moreover, we show that enforced expression of dominant-negative PI3K (DN-p85α) or phosphatidylinositol 3-phosphate-phosphatase, PTEN, also reverse the suppressive effect of IGF-I on TGF-β-induced 3TP-luciferase reporter activity, whereas constitutively active PI3K (p110αCAAX) completely blocks TGF-β-induced 3TP-luciferase reporter activity. Further transfection experiments including expression of constitutively active and dominant-negative Akt and rapamycin treatment suggest that suppression of TGF-β signaling/Smad3 activation by IGF-I occurs downstream of Akt and through mammalian target of rapamycin activation. In summary, our data suggest that IGF-I inhibits TGF-β transcriptional responses through selective suppression of Smad3 activation via a PI3K/Akt-dependent pathway. TGF-β, 1The abbreviations used are: TGF-β, transforming growth factor-β;TβR, TGF-β1 receptor; DMEM/F-12, Dulbecco's modified Eagle's medium/Ham's F-12; IGF-I, insulin-like growth hormone factor-I; LR3-IGF-I, long R3 IGF-I; IGF-IR, IGF-I receptor; DN, dominant negative; PI3K, phosphatidylinositol 3-kinase; CA, constitutively active; SARA, Smad anchor for receptor activation; mTOR, mammalian target of rapamycin; PTEN, phosphatase and tensin homologue deleted on chromosome 10; SRE, serum response element; SRF, serum response factor; NF-κB, nuclear factor κB; PH, pleckstrin homology; SH2, Src homology; SBE, Smad binding element; AP1, activator protein 1; CMV, cytomegalovirus; PI3P, phosphatidylinositol 3-phosphate; PI, phosphatidylinositol.1The abbreviations used are: TGF-β, transforming growth factor-β;TβR, TGF-β1 receptor; DMEM/F-12, Dulbecco's modified Eagle's medium/Ham's F-12; IGF-I, insulin-like growth hormone factor-I; LR3-IGF-I, long R3 IGF-I; IGF-IR, IGF-I receptor; DN, dominant negative; PI3K, phosphatidylinositol 3-kinase; CA, constitutively active; SARA, Smad anchor for receptor activation; mTOR, mammalian target of rapamycin; PTEN, phosphatase and tensin homologue delete
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Blume-Jensen, P., & Hunter, T. (2001) · Nature · doi:10.1038/35077225 · Cited by 3,738
Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN
Stambolic, V., Suzuki, A., de la Pompa, J. L., Brothers, G. M., Mirtsos, C., Sasaki, T., Ruland, J., Penninger, J. M., Siderovski, D. P., & Mak, T. W. (1998) · Cell · doi:10.1016/s0092-8674(00)81780-8 · Cited by 2,551
Isolation of a Protein Target of the FKBP12-Rapamycin Complex in Mammalian Cells
Sabers, C. J., Martin, M. M., Brunn, G. J., Williams, J. M., Dumont, F. J., Wiederrecht, G., & Abraham, R. T. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.2.815 · Cited by 887
Akt suppresses androgen-induced apoptosis by phosphorylating and inhibiting androgen receptor.
Lin, H.-K., Yeh, S., Kang, H.-Y., & Chang, C. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.121173298 · Cited by 401
TGF-β inhibits p70 S6 kinase via protein phosphatase 2A to induce G1 arrest
Petritsch, C., Beug, H., Balmain, A., & Oft, M. (2000) · Genes & Development · doi:10.1101/gad.854200 · Cited by 223
Cited by
The tor pathway: a target for cancer therapy
Bjornsti, M.-A., & Houghton, P. J. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1362 · Cited by 1,314
Signaling cross-talk between TGF-β/BMP and other pathways
Guo, X., & Wang, X.-F. (2009) · Cell Research · doi:10.1038/cr.2008.302 · Cited by 1,015
Akt interacts directly with Smad3 to regulate the sensitivity to TGF-β-induced apoptosis
Conery, A. R., Cao, Y., Thompson, E. A., Townsend, C. M., Ko, T. C., & Luo, K. (2004) · Nature Cell Biology · doi:10.1038/ncb1117 · Cited by 398
Adhami, V. M., Siddiqui, I. A., Ahmad, N., Gupta, S., & Mukhtar, H. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2840 · Cited by 296
Horowitz, J. C., Lee, D. Y., Waghray, M., Keshamouni, V. G., Thomas, P. E., Zhang, H., Cui, Z., & Thannickal, V. J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m306248200 · Cited by 239
Metadata
- Authors
- Song, K., Cornelius, S. C., Reiss, M., & Danielpour, D.
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2003-10
- Volume
- 278
- Issue
- 40
- Pages
- 38342-38351
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2074079253
- Cited by
- 98
- References
- 5
- FWCI
- 2.57
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.